Approved regulatory verdict
Evidence outlook
Approved: Chronic Myeloid Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Chronic Myeloid Leukemia · approved · Featured evidence · 3 approved Featured evidence · 3
Competitive landscape 1 competitor in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 1 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Ponatinib (ICLUSIG): this drug Approved Small molecule — ELVN-001 Phase 1 Small molecule —
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (16 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1) December 2026 (1) Phase 1/2 Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma Recruiting
Est. primary completion 2026-12-01 ·
NCT06207123 ·
CT.gov ↗ What to watch 2027 (5) February 2027 (2) Phase 2 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia … Recruiting
Est. primary completion 2027-02-01 ·
NCT03739814 ·
CT.gov ↗ What to watch Phase 2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1 … Active not recruiting
Est. primary completion 2027-02-28 ·
NCT03147612 ·
CT.gov ↗ What to watch September 2027 (1) Phase 3 Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL Active not recruiting
Est. primary completion 2027-09 ·
NCT04722848 ·
CT.gov ↗ What to watch October 2027 (1) Phase 2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia … Active not recruiting
Est. primary completion 2027-10-31 ·
NCT01424982 ·
CT.gov ↗ What to watch November 2027 (1) Phase 2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression … Recruiting
Est. primary completion 2027-11-30 ·
NCT03263572 ·
CT.gov ↗ What to watch 2028 (5) February 2028 (2) Phase 1/2 Chronic Myeloid Leukemia Recruiting
Est. primary completion 2028-02-01 ·
NCT03934372 ·
CT.gov ↗ What to watch Phase 2 Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor Recruiting
Est. primary completion 2028-02-17 ·
NCT06813079 ·
CT.gov ↗ What to watch March 2028 (1) Phase 2 Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia Recruiting
Est. primary completion 2028-03-01 ·
NCT04747912 ·
CT.gov ↗ What to watch July 2028 (2) Phase 3 B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Active not recruiting
Est. primary completion 2028-07-01 ·
NCT04530565 ·
CT.gov ↗ What to watch Phase 2 B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 … Recruiting
Est. primary completion 2028-07-31 ·
NCT07224100 ·
CT.gov ↗ What to watch 2029 (3) February 2029 (1) Phase 2 Chronic Myeloid Leukemia Recruiting
Est. primary completion 2029-02-17 ·
NCT06514534 ·
CT.gov ↗ What to watch June 2029 (1) Phase 2 Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia Active not recruiting
Est. primary completion 2029-06-01 ·
NCT04070443 ·
CT.gov ↗ What to watch July 2029 (1) Phase 2 Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting
Est. primary completion 2029-07-01 ·
NCT06061094 ·
CT.gov ↗ What to watch 2030 (1) December 2030 (1) Phase 2 Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive … Recruiting
Est. primary completion 2030-12-31 ·
NCT01746836 ·
CT.gov ↗ What to watch 2035 (1) March 2035 (1) Phase 2/3 Acute Lymphoblastic Leukemia Recruiting
Est. primary completion 2035-03-15 ·
NCT06860269 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (61) Chronic Myeloid Leukemia (15) Other / comorbidity (46)
Phase 3 (5) Phase 2/3 (2) Phase 2 (42) Phase 1/2 (8) Phase 1 (3) Early phase / not applicable (1) Appears in other studies (2)